Continuing Education (CME)
2023 SNO Pediatric Neuro-Oncology Research Conference
June 22-24, 2023
This activity is provided by the Society for Neuro-Oncology.
Pediatric neuro-oncologists, medical oncologists, neurosurgeons, radiation oncologists, radiologists, physician/scientists, clinical and laboratory trainees, and allied health professionals.
Statement of Need/Program Overview
The SNO 7th Biennial Pediatric Neuro-Oncology Research Conference will be held June 22-24, 2023, in Washington, D.C. at the Capital Hilton.
Building on the success of our previous pediatric meetings, this biennial conference encourages the sharing of ideas and results, new collaborations and offers attendees a state-of-the-art update in the field of pediatric brain tumor research. The scientific program will offer outstanding keynotes, panel discussions and abstract presentations on a range of timely themes shaping the future of pediatric neuro-oncology. Topics the conference will include developmental origins of pediatric brain tumors, novel approaches in cancer neuroscience, artificial intelligence, and machine learning, focused ultrasound/drug delivery, diversity & inclusion, novel immunotherapeutic findings, clinical trial reports, and single cell approaches to decipher molecular landscapes. Conference participants will also have opportunities to present their work — and to learn about advances made by others — through short oral presentations and scientific posters selected by the abstract review committee.
After participating in this CME activity, participants should be able to:
- Cite the developmental origins of pediatric brain tumors.
- Summarize the interactions between normal cells of the nervous system and cancer cells.
- Explain how artificial intelligence and machine learning approaches can leverage big genomic data sets in cancer biology towards improved treatment options for pediatric patients with CNS tumors.
- Identify new therapeutic delivery options that effectively treat pediatric patients with brain tumors protected by the blood brain barrier.
- Summarize recent advances in the experimental and clinical approach to the treatment of pediatric patients with brain tumors
- Identify recent developments and advances in translational and correlative biology and implications for discovery of novel treatments for pediatric patients with brain tumors.
Physician Accreditation Statement
The Society for Neuro-Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
The Society for Neuro-Oncology designates this live activity for a maximum of 18.75 AMA PRA Category 1 Credits™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit
The deadline for cancellations with refund is Friday, June 9, 2023. Cancellations must be received in writing and a $50 cancellation fee will be assessed. Cancellations received after the deadline date cannot be refunded, but the meeting registration can be transferred to another person with written authorization.
Please note that your SNO membership must be current if you have chosen to register as a SNO member. SNO reserves the right to confirm that you have registered in the correct category.
Payment must be received in full before access to the meeting can be granted.
Email all cancellation and transfer requests to Program Registrar Caroline Noor, [email protected]
Disclosure of Relevant Financial Relationships
SNO CME Contact Information
The Society for Neuro-Oncology (SNO) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME), stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of accredited continuing education program are required to disclose all financial relationships with any ineligible company within the past 24 months . All financial relationships reported are identified as relevant and mitigated by Society for Neuro-Oncology in accordance with the Standards for Integrity and Independence in Accredited Continuing Education in advance of delivery of the activity to learners. The content of this activity has been vetted to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by SNO.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Society for Neuro-Oncology does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For information about the accreditation of this program, please contact the Society for Neuro-Oncology CME Program Manager, MeLesa Ritterhouse, RN at [email protected]
Click here to return to the 2023 SNO Pediatric Conference homepage.